An investor, who purchased NYSE:DPLO shares, filed a lawsuit against Diplomat Pharmacy Inc over alleged Securities Laws violations.
Investors who purchased shares of Diplomat Pharmacy Inc (NYSE:DPLO) have certain options and for certain investors are short and strict deadlines running. Deadline: January 9, 2016. Diplomat Pharmacy Inc (NYSE:DPLO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The plaintiff claims that between October 9, 2014 and November 2, 2016 the Defendants made false and/or misleading statements and/or failed to disclose that Diplomat Pharmacy Inc lacked adequate internal controls over its financial reporting, that as a result Diplomat Pharmacy Inc could not adequately calculate DIR fees, that the Company’s hepatitis C segment was not performing as previously disclosed to investors, that and therefore, Diplomat Pharmacy Inc had overstated its full-year 2016 guidance, and that that, as a result of the foregoing, Defendants’ statements about Diplomat Pharmacy Inc’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Diplomat Pharmacy Inc reported that its annual Total Revenue rose from over $1.51 billion in 2013 to over $3.36 billion in 2015 and that its Net loss of $26.12 million in 2013 turned into a Net Income of $25.78 million in 2015.
On November 2, 2016, Diplomat Pharmacy Inc reported third quarter 2016 results. Diplomat Pharmacy Inc also lowered full year 2016 guidance, with the CEO and Chairman commenting, “We are disappointed with our third quarter results, which were significantly impacted by the softness in the hepatitis C business nationwide, as well as by DIR fees. The methodology and transparency around how PBMs are applying these DIR fees changed materially in 2016, and while we cannot reverse the impact they had on this quarter, we are working with our partners in the specialty pharmacy industry and with legislators to achieve an amicable solution to this problem.” Shares of Diplomat Pharmacy Inc (NYSE:DPLO) declined to as low as $12.47 per share on November 4, 2016.
On November 25, 2016, NYSE:DPLO shares closed at $15.03 per share.
Those who purchased NYSE:DPLO shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com